about
Novel immunotherapies in lymphoid malignanciesCAR T Cell Therapy: A Game Changer in Cancer TreatmentGenetically modified T cells in cancer therapy: opportunities and challengesCD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaFCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical RelevanceRegression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor.CAR-T Cell Therapies From the Transfusion Medicine PerspectiveA new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.Adoptive Cell Therapy in Multiple Myeloma.The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma.Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.SHP-1: the next checkpoint target for cancer immunotherapy?Engineered T cells: the promise and challenges of cancer immunotherapy.Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.Chimeric antigen receptors: driving immunology towards synthetic biology.Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update.The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicityChimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.CAR-T cells: the long and winding road to solid tumors.Trial Watch: Adoptively transferred cells for anticancer immunotherapy.Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies.Exploiting Cell Death Pathways for Inducible Cell Elimination to Modulate Graft-versus-Host-Disease.Synthetic immunology: T-cell engineering and adoptive immunotherapy
P2860
Q26777394-950FA89A-2A14-4079-8C04-307CFA8B643CQ26822769-B4425A35-2ADB-4C49-A643-86081EC07AE0Q27026627-A6072EFB-4F60-4B78-B824-45BBCA8B33C1Q28084879-635E3CAB-BA70-42F9-A656-FC6DC525DA5AQ33607015-DB4B3C4C-E6E0-4384-9B49-CFB2E4B07CDBQ36664207-3AC2DF8F-F62A-472E-82FA-7506E5EA63F3Q37022738-8B8155DB-5B8A-44CE-A01E-4FDE5633BCD0Q37555940-C9CA5A28-DC76-4ACD-9D31-8C3A901C61E6Q38391533-B197039F-6093-42B8-BC73-8525A31E669DQ38635138-4C3475B4-6000-4C7E-A981-8DEE51EC5F80Q38748836-C425CD8B-BEBA-46E1-9685-3AE156B512AFQ38764944-2A28A6E6-6869-417E-B1E3-3FD00CAE53CAQ38787449-6AF9B585-804F-4EA5-8187-B14B21BA2FDFQ38805738-DFD327A2-99BA-41AB-BBF7-6C39B2629F4CQ38828829-FFB5D3D8-CB09-43A5-86D0-2C1EACE88323Q38873430-1E2E5CDD-FB77-449B-99E4-B8D9C5AD7C16Q38884383-D9560EF0-C3CA-42C1-A29E-64F80BFD61F2Q38891877-12161C8D-E498-441E-8AA6-6488EA858FA4Q38987239-EC7BE3A8-D80C-4E34-85C5-461668F8A5F3Q39189908-AE9A8118-27AD-4E23-A835-BBF9AEF25265Q39246685-60187E90-21AA-42E3-90BB-BF670B2F9EEDQ39280002-A59E5829-AB34-460E-ADB8-0D9876564CD1Q42576424-59BCA299-E68F-4946-9BF2-9B89D7852AD7Q42657377-10FCA464-E066-490F-8BE1-65B1F3F6D4ABQ47561397-18E23000-FCE8-4F07-AD78-FA128CEDACEFQ49280922-9BC25BBA-4C2D-4420-A3D4-A44AD2EED3B3Q49959264-8FE29347-4529-44D1-AB3A-F0AF1D20F4CCQ52780137-229A160E-DCD9-4721-A83E-9DFC116D7B5AQ55216327-64DFA8DE-96CD-4DD8-9CFB-755BC2EA7E03Q55245977-7F0074C1-A051-43CA-B31A-B01FB5FB9608Q57823195-135E19EC-F4FB-4279-B403-22BBA22F264A
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
CD28z CARs and armored CARs
@en
type
label
CD28z CARs and armored CARs
@en
prefLabel
CD28z CARs and armored CARs
@en
P2093
P2860
P1433
P1476
CD28z CARs and armored CARs
@en
P2093
Hollie J Pegram
Jae H Park
Renier J Brentjens
P2860
P304
P356
10.1097/PPO.0000000000000034
P577
2014-03-01T00:00:00Z